Irrisept: Redefining Irrigation by Koening, Nicole
CentraCare Health
DigitalCommons@CentraCare Health
Nursing Posters Posters and Scholarly Works
2018
Irrisept: Redefining Irrigation
Nicole Koening
St. Cloud Hospital, CentraCare Health, koenign@centracare.com
Follow this and additional works at: https://digitalcommons.centracare.com/nursing_posters
Part of the Other Nursing Commons, and the Perioperative, Operating Room and Surgical
Nursing Commons
This Book is brought to you for free and open access by the Posters and Scholarly Works at DigitalCommons@CentraCare Health. It has been accepted
for inclusion in Nursing Posters by an authorized administrator of DigitalCommons@CentraCare Health. For more information, please contact
schlepers@centracare.com.
Recommended Citation
Koening, Nicole, "Irrisept: Redefining Irrigation" (2018). Nursing Posters. 96.
https://digitalcommons.centracare.com/nursing_posters/96
WHAT IS IRRISEPT?
IrriSept is a patented jet lavage system, containing low concentration chlorhexidine
gluconate (CHG) 0.05% in sterile water for irrigation, to clean a wound.
ABOUT THE IRRISEPT
• IrriSept is the only FDA-cleared device that delivers a pressurized
solution containing Chlorhexidine Gluconate (CHG) for cleansing and
debridement. As a final rinse, prior to closure in surgical procedures,
IrriSept has the potential to help reduce SSIs and associates treatment
costs. IrriSept was developed with the goal of becoming the “Standard
of Care” and improving patient outcomes.
• IrriSept has a wide range of activity against gram positive and gram
negative bacteria, fungi, and viruses. It has demonstrated
antimicrobial efficacy and persistence in laboratory testing.
SURGICAL SITE INFECTIONS
• Surgical site infections (SSIs) are the costliest hospital infections among
hospitalized patients. In the U.S. approximately 300,000 SSIs occur
yearly, representing 13% of healthcare associated infections.
• SSIs have a major impact on hospital’s financial performance. An
average cost of a SSI is approximately $30,000. The cost of using
IrriSept at $60 on 500 patients is $30,000. With the average cost of a
single SSI at $30,000, a reduction of just one SSI occurrence could
cover the total cost of using IrriSept on approximately 500 patients.
OTHER CONSIDERATIONS
Financial implications are not the only concern for hospitals and patients.
There are many other potentially adverse consequences as a result of high
SSIs rates:
• Reduced reimbursement
• Higher morality rates
• Increased re-admissions and overall length of stay
• Additional antibiotic usage
• Potential liability issues
• Potential reputational issues for the facility and surgeon
SCH SURGICAL SITE INFECTION RATES FOR Q3 
FY17 (JAN-MAR 2017) 
Primary focus on decreasing infection rates in colon surgery patients 
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University of South Florida conducted a study at Tampa
General Hospital
• The study demonstrated a significant decrease in SSIs
in colorectal operations with the consistent use of
IrriSept during a 7 month period.
• A total of 196 qualifying cases were performed prior to
the IrriSept intervention and 197 during the trail
period. A total of 27 SSIs occurred in each of the time
periods. Table 1: demonstrates the number and rates
of SSIs occurring during each time period and the
difference between surgeons.
A project through the University of Delaware using
IrriSept was introduced in a 26-facility acute care
system starting June 2015 to reduce colon surgical site
infections.
• The procedure involved irrigating the tissues after
the fascia was closed with Irrisept, leaving it in the
tissues for 1minute, followed by a rinse with saline.
• The study concluded that since IrriSept is a biocide
and and can efficiently attach to tissues it creates a
residual antibacterial effect that can last for many
days in the tissues.
August 2015 5.88 April 2016 1.28
September 2015 6.21 May 2016 1.49
October 2015 3.24 June 2016 2.43
November 2015 2.13 July 2016 1.05
December 2015 2.65 August 2016 2.24
January 2016 3.47 September 2016 2.01
February 2016 4.37 October 2016 3.18
March 2015 3.33 November 2016 1.09
Month-Year and Rate/100 Procedures
RECENT STUDIES USING IRRISEPT TO REDUCE SURGICAL SITE 
INFECTIONS IN COLORECTAL SURGERY
SAFETY CONSIDERATIONS AND POST-
MARKETING STUDIES
IrriSept has conducted post-marketing studies that have generated
safety testing regarding cytotoxicity, sensitization, and irrigation.
The testing data is summarized below:
• Intraperitoneal Organ Toxicity: The final report states that,
under conditions of the study, there were no significant adverse
findings associated with the test article in the tissue evaluated
• Acute Systemic Toxicity: The study objective was to
demonstrate the safety of Irrisept through evaluation of
systemic toxicity in a mouse model. There was no mortality and
no necropsy at 7 days and there was no evidence of systemic
toxicity from either portions of the test article.
• Neurotoxicity: The study objective was to demonstrate safety if
the Irrisept solution without normal saline rinse through
evaluation of systemic and neurological toxicity and local effects
after implantation in a chronic rabbit dorsal laminectomy model.
Results demonstrated that the IrriSept solution without a rinse is
a non-irritant, is comparable to saline control when evaluated
histologically, and therefore did not exhibit neurological toxicity.
• Hemolysis: Analysis of the study endpoints indicate that IrriSept
does not have more hemolytic potential than normal saline.
• Pharmacokinetics: Administration of IrriSept does result in
measurable levels of gluconate in the blood. Those levels rapidly
decrease within 3 hours of administration, almost to baseline.
The administration of IrriSept did not result in any observable
adverse effects with respect to peritoneal organs.
Presented by:
Nicole Koenig, RN, CNOR, TNCC
St. Cloud Hospital, St. Cloud, MN
